Dr Erika Sims
| Job Title | Contact | Location |
|---|---|---|
| Honorary Research Fellow |
E dot Sims at uea dot ac dot uk
Tel: +441263735903 |
Career
- Research Assistant on project entitled ‘Predicting Drug Absorption From the Gastrointestinal Tract’, University of Manchester. 1993 to 1997
- Research Assistant and Clinical Trials Coordinator, Asthma & Allergy Research Group, University of Dundee. 1997 to 2000
- Postdoctoral Research Fellow and Clinical Trials Coordinator, Asthma & Allergy Research Group, University of Dundee. 2000 to 2001
- UK CF Database Fellow, Maternal & Child Health Sciences, University of Dundee, 2001 to 2004
- Research Associate and UK CF Database Fellow, Institute of Health, University of East Anglia, 2004 to current.
Academic Background
- BSc(Hons) in Biomedical Technology, Sheffield Hallam University, 1993
- PhD entitled ‘Regulation of Epithelial Tight Junctions’, Schools of Medicine and Pharmacy, University of Manchester, 2000.
Key Research Interests
My research interests are three fold:
1. Establishing the potential clinical and economic benefit of newborn screening for cystic fibrosis in the UK.
2. Evaluating the impact of models of health care delivery in the management of chronic disease in terms of clinical outcomes, direct and indirect costs and quality of life.
3. Identifying factors that A) predispose to cystic fibrosis related diabetes and B) affect the rate of CF disease progression subsequent to cystic fibrosis related diabetes diagnosis.
Research Group Members
Teaching Interests
- Assessor on the MBBS Epidemiology Module.
- Organised and conducted in-house staff training on theoretical and practical elements of laboratory techniques used in respiratory function, airway inflammation and bronchial challenge testing (1999-2001).
Article
Price, D, Musgrave, S, Shepstone, L, Hillier, E, Sims, E, Gilbert, R, Juniper, E, Ayres, J, Kemp, L, Blyth, A, Wilson, E, Wolfe, S, Freeman, D, Mugford, M, Murdoch, J and Harvey, I (2011) Leukotriene antagonists as first-line or add-on asthma controller therapy. The New England Journal of Medicine, 364 (18). pp. 1695-1707. ISSN 0028-4793
Price, D, Musgrave, S, Wilson, E, Sims, E, Shepstone, L, Blyth, A, Murdoch, J, Mugford, M, Juniper, E, Ayres, J, Wolfe, S, Freeman, D, Lipp, A, Gilbert, R and Harvey, I (2011) A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study). Health technology assessment (Winchester, England), 15 (21). pp. 1-132. ISSN 1366-5278
Wilson, E, Price, D, Musgrave, SD, Sims, EJ, Shepstone, L, Murdoch, J, Mugford, M, Blyth, A, Juniper, E, Ayres, J, Wolfe, S, Freeman, D, Gilbert, R, Hillyer, E and Harvey, IM (2010) The cost effectiveness of leukotriene receptor antagonists versus long acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. Pharmacoeconomics, 28 (7). pp. 597-608.
Wilson, E, Sims, EJ, Musgrave, SD, Shepstone, L, Blyth, A, Murdoch, J, Mugford, M, Juniper, E, Ayres, J, Wolfe, S, Freeman, D, Gilbert, R, Harvey, IM, Hillyer, E and Price, D (2010) The cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. Pharmacoeconomics, 28 (7). pp. 585-595.
Sims, EJ, Clark, AB, McCormick, J, Metha, G, Connett, G and Metha, A (2007) Cystic fibrosis diagnosed after two months of age leads to worse outcomes and requires more therapy. Pediatrics, 119 (1). pp. 19-28.
Sims, EJ, Mugford, M, Clark, AB, Aitken, D, McCormick, J, Mehta, G and Mehta, A (2007) Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. The Lancet, 369 (9568). pp. 1187-1195.
McCormick, J, Sims, EJ and Mehta, A (2006) A delayed diagnosis of females with respiratory presentation of cystic fibrosis did not segregate with poorer clinical outcome. Journal of Clinical Epidemiology, 59 (3). pp. 315-322.
Lipworth, BJ, Sims, EJ, Das, SK, Buck, H and Paterson, M (2005) Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge. Ann Allergy Asthma Immunol, 94 (6). pp. 675-681.
Lipworth, BJ, Sims, EJ, Das, SK, Morice, AH and O'Connor, BJ (2005) Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. Ann Allergy Asthma Immunol, 95 (3). pp. 283-290.
Lipworth, BJ, Sims, EJ, Taylor, K, Cockburn, W and Fishman, R (2005) Dose-response to albutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. British Journal of Clinical Pharmacology, 59 (1). pp. 5-13.
McCormick, J, Ogston, SA, Sims, EJ and Mehta, A (2005) Asians with cystic fibrosis in the UK have worse disease outcomes than clinic matched white homozygous delta F508 controls. Journal of Cystic Fibrosis, 4 (1). pp. 53-58.
McCormick, J, Sims, EJ, Green, MW, Mehta, G, Culross, F and Mehta, A (2005) Comparative analysis of Cystic Fibrosis Registry data from the UK with USA, France and Australasia. Journal of Cystic Fibrosis, 4 (2). pp. 115-122.
Sims, EJ, Green, M and Mehta, A (2005) Decreased Lung Function in Female but not Male Subjects With Established Cystic Fibrosis-Related Diabetes. Diabetes Care, 28 (7). pp. 1581-1587.
Sims, EJ, McCormick, J, Mehta, G and Mehta, A (2005) Newborn screening for cystic fibrosis is associated with reduced treatment intensity. Pediatrics, 147 (3). pp. 306-311.
Mehta, G, Sims, EJ, Culross, F, McCormick, JD and Mehta, A (2004) Potential benefits of the UK Cystic Fibrosis Database. Royal Society of Medicine, 97 (Suppl 44). pp. 60-71.
Sims, EJ and Lipworth, BJ (2004) Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype. European Journal of Clinical Pharmacology, 59 (11). pp. 791-795.
Lee, DK, Robb, FM, Sims, EJ, Currie, GP, McFarlane, LC and Lipworth, BJ (2003) Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. British Journal of Clinical Pharmacology, 55 (3). pp. 310-313.
Sims, EJ, Jackson, CM and Lipworth, BJ (2003) Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype. British Journal of Clinical Pharmacology, 56 (1). pp. 104-111.
Wilson, AM, Coutie, WJ, Sims, EJ and Lipworth, BJ (2003) The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients. European Journal of Clinical Pharmacology, 58 (10). pp. 643-647.
Wilson, AM, Orr, LC, Robb, F, Sims, EJ and Lipworth, BJ (2003) Reproducibilty of nasal function measurements with histamine and adenosine monophosphate nasal challenge testing in patients with allergic rhinitis. Allergology International, 52 (3). pp. 155-160.
Wilson, AM, Sims, EJ, Orr, LC, Robb, F and Lipworth, BJ (2003) An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. British Journal of Clinical Pharmacology, 55 (4). pp. 354-359.
Wilson, AM, Sims, EJ, Robb, F, Cockburn, W and Lipworth, BJ (2003) Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology, 41 (1). pp. 16-20.
Currie, GP, Fowler, SJ, Wilson, AM, Sims, EJ, Orr, LC and Lipworth, BJ (2002) Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax, 57 (10). pp. 865-868.
Fowler, SJ, Orr, LC, Sims, EJ, Wilson, AM, Currie, GP, McFarlane, LC and Lipworth, BJ (2002) Therapeutic ratio of hydrofluroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest, 58. pp. 187-190.
Sims, EJ, Wilson, AM, White, PS, Gardiner, Q and Lipworth, BJ (2002) Short-term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology, 40 (2). pp. 66-68.
Wilson, AM, Haggart, K, Sims, EJ and Lipworth, BJ (2002) Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clinical and Experimental Allergy, 32 (10). pp. 1504-1509.
Wilson, AM, Orr, LC, Coutie, WJ, Sims, EJ and Lipworth, BJ (2002) A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clinical and Experimental Allergy, 32 (1). pp. 126-132.
Fowler, SJ, Orr, LC, Wilson, AM, Sims, EJ and Lipworth, BJ (2001) Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. British Journal of Clinical Pharmacology, 52. pp. 93-95.
Wilson, AM, Dempsey, OJ, Sims, EJ and Lipworth, BJ (2001) Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest, 119 (4). pp. 1021-1026.
Wilson, AM, Dempsey, OJ, Sims, EJ and Lipworth, BJ (2001) A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clinical and Experimental Allergy, 31 (4). pp. 616-624.
Wilson, AM, Orr, LC, Sims, EJ and Lipworth, BJ (2001) Effects of monotherapy with intra-nasal corticosteroid or combines oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clinical and Experimental Allergy, 31. pp. 61-68.
Wilson, AM, Sims, EJ, Orr, LC, Coutie, WJ, White, PS, Gardiner, Q and Lipworth, BJ (2001) Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol, 87. pp. 344-349.
Wilson, AM, Dempsey, OJ, Sims, EJ, Coutie, WJ, Paterson, M and Lipworth, BJ (2000) Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clinical and Experimental Allergy, 30 (6). pp. 833-838.
Wilson, AM, Dempsey, OJ, Sims, EJ and Lipworth, BJ (2000) Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol, 85. pp. 111-114.
Wilson, AM, Dempsey, OJ, Sims, EJ, Mistry, C and Lipworth, BJ (2000) Addictive bronchoprotection and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest, 117. pp. 950-953.
Wilson, AM, Orr, LC, Sims, EJ, Dempsey, OJ and Lipworth, BJ (2000) Anti-asthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. American Jornal of Respiratory and Critical Care Medicine, 162. pp. 1297-1301.
Wilson, AM, Dempsey, OJ, Coutie, WJ, Sims, EJ and Lipworth, BJ (1999) Importance of drug-device interaction in determining systemic effects of inhales corticosteroids. Lancet, 353 (9170). p. 2128.
Wilson, AM, Sims, EJ and Lipworth, BJ (1999) Does a response with fluticasasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Cleveland Clinic Journal of Medicine, 50. pp. 329-335.
Wilson, AM, Sims, EJ and Lipworth, BJ (1999) Does response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clinical Endocrinology, 50. p. 329.
Wilson, AM, Sims, EJ, Struthers, AD and Lipworth, BJ (1998) Inhaled corticosteroid therapy reduces early morning peak in cortisol and aldosterone. Clinical Science, 95. pp. 513-517.
External Activities and Indicators of Esteem
- 2005 North American Cystic Fibrosis Conference – Travel Award
- 2004 North American Cystic Fibrosis Conference – Travel Award
- 2003 North American Cystic Fibrosis Conference – Travel Award
- 2000 National Asthma Campaign, Henry Blair Prize for a project aimed at raising awareness of Allergy and Asthma within the local community.
- 1996 Biochemical Society, Travel Award to attend 45th Harden Conference, Tunbridge Wells, UK
Professional Activities
- RA Representative on IOH Executive Committee (October 2006 onwards)
